交易 Vir Biotechnology VIR

出售
 买入

VirBiotechnology 实时图表

5m 15m 30m 1h 4h 1d 1w

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%)： 开盘价 高 低

VirBiotechnology news

最新新闻

显示更多
Frances Wang 2025 Jun 25, 16:00

Stock Mover Today: Why BAC Stock Is Trending Now?

Stocks
Frances Wang 2025 Jun 25, 16:00

MSTR Stock News: MSTR Shares Rise 1.9% Amid Mixed Options Market Sentiment

Stocks
Ghko B 2025 Jun 25, 16:00

Stock indexes today: Dow Jumps 500 Points, S&P 500 Rises on Trump Ceasefire

Stocks
Frances Wang 2025 Jun 24, 16:00

Value of bitcoin today: BTC/USD over 106K as Middle East tensions eased

Cryptocurrencies
Frances Wang 2025 Jun 24, 16:00

Market movers today: Carnival, Tesla, Mastercard, SOFI

Stocks
Tommy Yap 2025 Jun 24, 16:00

Morning Note: Ceasefire Boosts Markets; Dovish Fed & RBA Rate Cut Bets Emerge

Morning Note Stocks Forex
Tommy Yap 2025 Jun 24, 16:00

Morning Note: Powell on Tariffs; Oil Rebounds; Aussie Inflation Cools

Morning Note Commodities Forex
Ghko B 2025 Jun 23, 16:00

IBO stock up 200% today: what’s going on with Impact Biomedical

Stocks

信息

点差

0.12

点差(%)

2.3438 %

杠杆

1:10

隔夜利息（买入）

-0.0597 %

隔夜利息（卖出）

-0.0292 %

币种

USD

交易时间

市场开放

星期四

13:31 - 19:59

星期一

13:31-19:59

星期二

13:31-19:59

星期三

13:31-19:59

星期五

13:31-19:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

728514240

在外流通股份

138238000

财报日（下一）

0000-00-00

股息收益率

除息日

远期年度股息率

0

远期年股息率

0

每股收益

-4.23

详细了解此金融票据

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

相关金融票据

资产
出售
买入
更改(%)：

立即交易

立即交易

立即交易

立即交易
相关金融票据

latest_education_articles

显示更多
Trustpilot